Multiple Sclerosis Phenotypes as a Continuum
The Role of Neurologic Reserve
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 6, 2020
- Accepted December 10, 2020
- First Published January 29, 2021.
Article Versions
- Previous version (January 29, 2021 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Timothy L. Vollmer, MD,
- Kavita V. Nair, MD,
- Ian M. Williams, PhD and
- Enrique Alvarez, MD
- Timothy L. Vollmer, MD,
(1) Genentech/Roche
NONE
NONE
NONE
(1) Combination therapy of rituximab and glatiramer acetate
NONE
(1) University of Colorado School of Medicine
(1) Biogen, (2) Genentech/Roche, (3) Siranax, (4) Celgene, (5) EMD Serono, (6) Novartis
NONE
NONE
NONE
(1) Celgene, (2) Biogen, (3)Anokion, (4) Genentech, (5) F. Hoffmann-La Roche Ltd, (6) GW Pharma, (7) TG Therapeutics, Inc.
NONE
NONE
(1) Rocky Mountain MS Center
NONE
NONE
NONE
NONE
NONE
NONE
- Kavita V. Nair, MD,
Novartis
NONE
Commercial or non profit entity American Academy of Neurology
NONE
NONE
NONE
NONE
Bristol Meyers Squibb Novartis Genentech
NONE
NONE
NONE
Novartis, Genentech
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ian M. Williams, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
Oxford PharmaGenesis Ltd, Communications Consultant, 4+ years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Enrique Alvarez, MD
Actelion/Janssen, Alexion, Bayer, Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Genzyme, Novartis, Sanofi, and TG Therapeutics
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Genentech/Roche, Novartis, TG Therapeutics,
Patient-Centered Outcomes Research Initiative, National Institutes of Health
NONE
National Multiple Sclerosis Society, and Rocky Mountain MS Center
NONE
NONE
NONE
NONE
NONE
NONE
- Department of Neurology (TLV, KVN, EA), University of Colorado, and Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora; Department of Clinical Pharmacy (KVN), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora; and Oxford PharmaGenesis (IMW), United Kingdom.
- Correspondence
Prof. Vollmer Timothy.Vollmer{at}ucdenver.edu
Article usage
Cited By...
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- Is There Evidence That Progressive and Relapsing MS Are Distinct Conditions?
- What Does Explain the Different MS Phenotypes?
- Reducing MS Comorbidities and Protecting Neurologic Reserve Through Diet and Physical Activity
- Pharmacologic Treatment of PrMS: What Do Clinical Trial Results Suggest?
- Conclusions
- Study Funding
- Disclosure
- Appendix Authors
- Footnotes
- References
- Figures & Data
- Info & Disclosures
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Review
Secondary Progressive Multiple SclerosisNew InsightsBruce A.C. Cree, Douglas L. Arnold, Jeremy Chataway et al.Neurology, June 04, 2021 -
Views & Reviews
Defining the clinical course of multiple sclerosisThe 2013 revisionsFred D. Lublin, Stephen C. Reingold, Jeffrey A. Cohen et al.Neurology, May 28, 2014 -
Views & Reviews
Serum neurofilament light as a biomarker in progressive multiple sclerosisRaju Kapoor, Kathryn E. Smith, Mark Allegretta et al.Neurology, July 16, 2020 -
Articles
Familial effects on the clinical course of multiple sclerosisA. E. Hensiek, S. R. Seaman, L. F. Barcellos et al.Neurology, January 29, 2007